Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Asset Writedowns and Impairment: 2010-2023

Historic Asset Writedowns and Impairment for Lifecore Biomedical (LFCR) over the last 8 years, with May 2023 value amounting to $1.3 million.

  • Lifecore Biomedical's Asset Writedowns and Impairment fell 240.20% to -$1.4 million in Q2 2024 from the same period last year, while for Feb 2024 it was $47.5 million, marking a year-over-year decrease of 38.44%. This contributed to the annual value of $1.3 million for FY2023, which is 98.34% down from last year.
  • Lifecore Biomedical's Asset Writedowns and Impairment amounted to $1.3 million in FY2023, which was down 98.34% from $78.1 million recorded in FY2022.
  • Lifecore Biomedical's Asset Writedowns and Impairment's 5-year high stood at $78.1 million during FY2022, with a 5-year trough of $1.3 million in FY2023.
  • For the 2-year period, Lifecore Biomedical's Asset Writedowns and Impairment averaged around $39.7 million, with its median value being $39.7 million (2022).
  • In the last 5 years, Lifecore Biomedical's Asset Writedowns and Impairment surged by 547.65% in 2020 and then tumbled by 98.34% in 2023.
  • Over the past 4 years, Lifecore Biomedical's Asset Writedowns and Impairment (Yearly) stood at $2.0 million in 2019, then soared by 547.65% to $13.0 million in 2020, then reached $78.1 million in 2022, then crashed by 98.34% to $1.3 million in 2023.